title: Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia.
abstract: It has been discussed if computed tomography (CT) scan is necessary to perform or not, to provide prognostic information in patients with chronic lymphocytic leukemia. In the current National Institute Chronic lymphocytic leukemia Working Group (NCI-WG) guidelines, CT scan is not recommended outside clinical trials but states that further trials are warranted. Computed tomography scan of lymphadenopathy and/or splenomegaly was detected in totally 74 patients, leading to a modified Rai stage in 9 (12%) patients (from stage I to II). Using CT, 19 patients fulfilled the GELF high tumor burden criteria and/or one bulky node > or =7 cm. CT showed splenomegaly in totally 54 (73%) patients, of which 22 (41%) cases had not had been detected during clinical examination. According to the NCI response criteria for chronic lymphocytic leukemia (CLL), 15 (22%) patients showed a CR and 43 (62%) a PR, while when including CT findings, 12 (17%) fulfilled criteria for CR and 41 (59%) for PR. Patients with a high lymphadenopathy tumor burden according to the GELF criteria at the time of initiation of first-line therapy had a shorter time from response to next therapy or death, 12 months compared with 35 months for patients with less advanced lymphadenopathy (P = 0.002). There was also a trend for a shorter overall survival in the high tumor burden group, 58 months compared to 75 months (P = 0.098). Massive splenomegaly was related to a shorter therapy-free as well as overall survival. In our opinion, clinical examination is not sufficient for evaluation of abdominal lymphnodes and spleen in patients with therapy requiring CLL.
authors.affiliation: Department of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
authors.forename: Stefan
authors.initials: S
authors.lastname: Norin
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
authors.forename: Jeanette
authors.initials: J
authors.lastname: Lundin
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D010173:Palpation; D011379:Prognosis; D012189:Retrospective Studies; D013154:Spleen / Q000473:pathology / Q000528:radiation effects; D013163:Splenomegaly / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D000970:Antineoplastic Agents
references.citation: Ann Oncol. 1996 Apr;7(4):373-9
references.pmid: 8805929
references.citation: J Clin Oncol. 2005 May 1;23(13):2971-9
references.pmid: 15738539
references.citation: Leukemia. 2007 May;21(5):956-64
references.pmid: 17361231
references.citation: Cancer. 1981 Jul 1;48(1):198-206
references.pmid: 7237385
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5624-9
references.pmid: 17984187
references.citation: Cancer. 2005 Sep 1;104(5):1066-74
references.pmid: 16047335
references.citation: N Engl J Med. 1993 Nov 25;329(22):1608-14
references.pmid: 8232429
references.citation: Br J Haematol. 2002 Mar;116(3):538-48
references.pmid: 11849209
references.citation: Blood. 2002 Aug 1;100(3):768-73
references.pmid: 12130484
references.citation: Hematol Oncol Clin North Am. 1990 Apr;4(2):447-56
references.pmid: 2182601
references.citation: J Clin Oncol. 1996 Jul;14(7):2160-6
references.pmid: 8683250
references.citation: J Clin Oncol. 1997 Apr;15(4):1567-74
references.pmid: 9193354
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Blood. 1975 Aug;46(2):219-34
references.pmid: 1139039
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1576-80
references.pmid: 17353549
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Blood. 1996 Jun 15;87(12):4990-7
references.pmid: 8652811
references.citation: Blood. 2006 Feb 1;107(3):885-91
references.pmid: 16219797
references.citation: Best Pract Res Clin Haematol. 2002 Sep;15(3):429-47
references.pmid: 12468398